105 related articles for article (PubMed ID: 15095621)
1. [Comparison of early bone histomorphometric effects of parathormone and alendronate in osteoporotic women].
Arlot M; Roux JP; Portero N; Boivin G; Meunier PJ
Rev Med Suisse Romande; 2004 Feb; 124(2):91-2. PubMed ID: 15095621
[TBL] [Abstract][Full Text] [Related]
2. [Effects of teriparatide and alendronate on bone mineral density of osteoporotic rats].
Li M; Jiao J; Meng XW; Xing XP; Xia WB; Zhou XY; Liu HC; Jiang Y; Wang O; Hu YY; Zhan ZW
Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(5):335-8. PubMed ID: 15854512
[TBL] [Abstract][Full Text] [Related]
3. [Parathyroid and bone. Evidence and perspective of parathyroid therapy for patients with osteoporosis].
Wada S; Fukawa T; Kamiya S
Clin Calcium; 2007 Dec; 17(12):1888-94. PubMed ID: 18057665
[TBL] [Abstract][Full Text] [Related]
4. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass.
McClung MR; San Martin J; Miller PD; Civitelli R; Bandeira F; Omizo M; Donley DW; Dalsky GP; Eriksen EF
Arch Intern Med; 2005 Aug 8-22; 165(15):1762-8. PubMed ID: 16087825
[TBL] [Abstract][Full Text] [Related]
5. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
[TBL] [Abstract][Full Text] [Related]
6. The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis.
Liu H; Michaud K; Nayak S; Karpf DB; Owens DK; Garber AM
Arch Intern Med; 2006 Jun; 166(11):1209-17. PubMed ID: 16772249
[TBL] [Abstract][Full Text] [Related]
7. Teriparatide: new preparation. Osteoporosis: less well evaluated than alendronic acid.
Prescrire Int; 2005 Feb; 14(75):5-9. PubMed ID: 15747448
[TBL] [Abstract][Full Text] [Related]
8. Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis.
Brixen KT; Christensen PM; Ejersted C; Langdahl BL
Basic Clin Pharmacol Toxicol; 2004 Jun; 94(6):260-70. PubMed ID: 15228497
[TBL] [Abstract][Full Text] [Related]
9. Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study.
Biermasz NR; Hamdy NA; Pereira AM; Romijn JA; Roelfsema F
Clin Endocrinol (Oxf); 2004 May; 60(5):568-75. PubMed ID: 15104559
[TBL] [Abstract][Full Text] [Related]
10. Is the current anti-osteoporotic therapy paradigm good enough?
Fisher AA; Davis MW
J Am Geriatr Soc; 2006 Dec; 54(12):1960-1, author reply 1961-3. PubMed ID: 17198519
[No Abstract] [Full Text] [Related]
11. Marked reduction of bone turnover by alendronate attenuates the acute response of bone resorption marker to endogenous parathyroid hormone.
Zikan V; Stepan JJ
Bone; 2009 Apr; 44(4):634-8. PubMed ID: 19150421
[TBL] [Abstract][Full Text] [Related]
12. The teriparatide in the treatment of severe senile osteoporosis.
Manuele S; Sorbello L; Puglisi N; Grasso S; La Malfa L; D'Urbino G; Rizzotto M; Strano S; Maugeri D
Arch Gerontol Geriatr; 2007; 44 Suppl 1():249-58. PubMed ID: 17317460
[TBL] [Abstract][Full Text] [Related]
13. [Human parathyroid hormone (1-34) as a new therapeutic agent for osteoporosis].
Isogai Y
Clin Calcium; 2005 Jan; 15(1):18-24. PubMed ID: 15632468
[TBL] [Abstract][Full Text] [Related]
14. [Teriparatide: an anabolic drug for the treatment of patients with osteoporosis].
Lems WF; Hamdy NA; Netelenbos JC
Ned Tijdschr Geneeskd; 2006 Jan; 150(3):132-7. PubMed ID: 16463613
[TBL] [Abstract][Full Text] [Related]
15. Effects of parathyroid hormone and alendronate alone or in combination in osteoporosis.
Miller PD
N Engl J Med; 2004 Jan; 350(2):189-92; author reply 189-92. PubMed ID: 14714279
[No Abstract] [Full Text] [Related]
16. Coming to grips with bone loss.
Marx J
Science; 2004 Sep; 305(5689):1420-2. PubMed ID: 15353792
[No Abstract] [Full Text] [Related]
17. μCT-based, in vivo dynamic bone histomorphometry allows 3D evaluation of the early responses of bone resorption and formation to PTH and alendronate combination therapy.
de Bakker CM; Altman AR; Tseng WJ; Tribble MB; Li C; Chandra A; Qin L; Liu XS
Bone; 2015 Apr; 73():198-207. PubMed ID: 25554598
[TBL] [Abstract][Full Text] [Related]
18. [Parathyroid hormone for osteroporsis: why and who to treat?].
Ferrari S; Rizzoli R
Rev Med Suisse; 2005 Oct; 1(35):2272-4, 2276-7. PubMed ID: 16268450
[TBL] [Abstract][Full Text] [Related]
19. The effects of alendronate on bone turnover and bone quality.
Meunier PJ; Arlot M; Chavassieux P; Yates AJ
Int J Clin Pract Suppl; 1999 Apr; 101():14-7. PubMed ID: 12669736
[TBL] [Abstract][Full Text] [Related]
20. Bone histomorphometry of transiliac paired bone biopsies after 6 or 12 months of treatment with oral strontium ranelate in 387 osteoporotic women: randomized comparison to alendronate.
Chavassieux P; Meunier PJ; Roux JP; Portero-Muzy N; Pierre M; Chapurlat R
J Bone Miner Res; 2014 Mar; 29(3):618-28. PubMed ID: 23959630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
